Investigating Miracles: Are They Supernatural, or Just Natural?
Learn more about your ad choices. Visit podcastchoices.com/adchoices
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
24-07-2025
- Hamilton Spectator
MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm', 'MediPharm Labs' or the 'Company'), a pharmaceutical company specializing in precision-based cannabinoids, is pleased to announce it has launched the new Shake & Puff CBN THC Nighttime Inhaler in Canada. This innovative product expands MediPharm's leading CBN oil product portfolio and builds on the success of the Company's THC Inhaler introduced earlier this year. The new metered dose inhaler delivers a precise formulation of minor cannabinoid CBN and THC in a consistent, smoke-free format. Designed for nighttime use, the product offers a fast onset experience without combustion or vapour, making it a discreet and convenient option for both consumers and medical patients. David Pidduck, CEO of MediPharm Labs, commented: 'The launch of our CBN THC Metered Dose Inhaler represents a significant step forward in our strategy to deliver innovative, pharma-grade cannabinoid products globally. As international markets increasingly seek smoke-free, precisely dosed formats, MediPharm is well-positioned to lead with differentiated solutions that reflect both consumer wellness trends and medical needs. This product not only strengthens our Canadian portfolio but also supports our broader vision to scale precision cannabinoid delivery methods across regulated cannabis markets worldwide.' Key Product Highlights: The Company plans to expand their inhaler offering with additional CBD and CBG options available in the future. MediPharm Labs continues to lead in pharma-grade cannabinoid innovation, offering a diverse range of product formats tailored to the evolving needs of consumers and patients. Inhaled formats like the metered dose inhaler provide rapid onset, while other MediPharm Labs products, such as tinctures, soft chews, and soft gels offer a slower onset and longer-lasting effects. About MediPharm Labs MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API), and advanced derivative products utilizing a Good Manufacturing Practices (GMP) certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies, and purpose-built facilities for the delivery of pure, trusted, and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages, and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA. In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical e-commerce platform, and in Australia and Germany through Beacon Medical PTY and Beacon Medical GMBH. This acquisition also included Harvest Medical Clinics in Canada, which provides medical cannabis patients with physician consultations for medical cannabis education and prescriptions. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. For further information, please contact: MediPharm Labs Investor Relations Telephone: +1 416.913.7425 Email: investors@ Website: Cautionary Note Regarding Forward-Looking Information: This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events, or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events, or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, MediPharm's access to and unique position in the international medical markets, MediPharm's future growth and ability to scale precision cannabinoid delivery methods across regulated cannabis markets worldwide, MediPharm's timing and ability to distribute its metered dose inhalers in Canada, MediPharm's ability to further expand its international portfolio, future growth of cannabinoid products in international markets, wellness trends and medical needs of consumers, and the success of MediPharm's products in Canada, including MediPharm's ability to expand distribution of its metered dose inhaler products to additional provinces and channels. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political, and social uncertainties; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs' filings, available on the SEDAR+ website at . There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change. A photo accompanying this announcement is available at
Yahoo
03-06-2025
- Yahoo
Philippine health agency quashes mpox lockdown rumours
"Don't dismiss this, please share! [The government] is trying to determine if the entire country should be placed on lockdown because of the danger of mpox," reads part of the Tagalog-language caption of a graphic shared on Facebook on May 31, 2025. It bears the logos of the Philippines' Department of Health and the World Health Organization, says the lockdown will start "June 10, 2025" and adds the use of face masks will be mandatory. The Facebook post also includes links to products sold on popular e-commerce sites Shopee and Lazada. Similar posts were shared elsewhere on Facebook, as were similar graphics about a June 6 lockdown purportedly shared by Philippine broadcaster ABS-CBN. "Oh no, here we go again, this is scary," read a comment on one of the posts. Another said: "And children are about to go back to school next month at the opening of the school year!" Multiple towns in the central and southern Philippines in May reported cases of mpox, a disease caused by a virus from the same family as smallpox that manifests itself in a high fever and skin lesions (archived here, here and here). But the archipelago's health department says there is no need to restrict the public's movement. According to the agency, the cases reported in May were caused by the mild Clade 2 variant -- not the highly transmissible Clade 1b strain of the virus that has killed hundreds of people in the Democratic Republic of Congo and was also detected in Burundi, Kenya, Rwanda, Uganda and Sweden (archived here and here). The Department of Health said in a May 31 statement that posts claiming a lockdown was imminent were "fake", and there was no need to restrict movement because mpox is not airborne (archived link). "Lockdown does not work for mpox. Why? Because it is [transmitted via] skin-to-skin contact, so there could be more skin-to-skin contact if there is a lockdown," health chief Ted Herbosa said in a press briefing on May 31 (archived link). Separately, the heath department and the Philippine Society for Microbiology and Infectious Diseases said mask mandates imposed by several localities in response to mpox cases were unnecessary and would not prevent the spread of the virus (archived here. here, here and here). There has also been no surge in the number of mpox cases in the country. According to information released by the health department, more cases were recorded in April than in May (archived link). The Philippines has not recorded any cases from Clade 1b. The lockdown graphic purportedly shared by ABS-CBN was also dismissed by the health agency as "fake" on May 31 (archived link). The graphic uses the same background of a genuine graphic shared by the broadcaster on its official Facebook page on May 28, 2020, at the height of the Covid pandemic (archived link). The original graphic was about Metro Manila being placed under "General Community Quarantine". AFP has debunked other false claims about mpox here.
Fox News
06-04-2025
- Fox News
Investigating Miracles: Are They Supernatural, or Just Natural?
Polls show the vast majority of people believe in miracles. But what is a miracle? When does a healing defy the laws of medicine? Investigative journalist and author Billy Hallowell journeyed through the realm of the supernatural and the natural to find out if miracles do happen, why they happen, and why they don't happen. On this episode of Lighthouse Faith podcast, Hallowell talks about his documentary 'Investigating the Supernatural: Miracles', now streaming on Christian Broadcasting Network (CBN). Hallowell says the bar was set pretty high to determine if someone indeed was miraculously healed, that there could be no other scientific reason for the healing. The investigation focuses on several different people including the case of Dr. Chauncey Crandall, a cardiologist who prayed over a patient who suffered a massive heart attack and had no pulse for 40 minutes. The patient was given one more jolt from the defibrillator after Crandall's prayers and his heart began beating. But that was only part of the miracle… The patient had no resulting brain damage. But why was Crandall's prayer for his patient answered, and yet years before his prayer for his own dying child was not? That, Hallowell says, is part of the mystery of our walk with God in searching for a miracle. Learn more about your ad choices. Visit
